Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Welcome and Introduction to Vi3C

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Amit Sanyal, MD: A Clinician’s Perspective

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Advertisement

Advertisement




Oct
09
Today In Oncology
HER2-Positive Breast Cancer FDA Approves Triplet for Maintenance Therapy
FDA Approves First-Line Pirtobrutinib for CLL-SLL
FDA Approves Lirafugratinib for Previously Treated, Unresectable, Locally Advanced or Metastatic Cholangiocarcinoma
FDA Approves New Labeling of ROS1 Inhibitor for NSCLC
Charles Perou 2026 William L. McGuire Memorial Lecture Award
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo